NCT03467256

A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia

Study Summary

The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia

Want to learn more about this trial?

Request More Info

Interventions

Chimeric Antigen Receptor T-Cell TherapyBIOLOGICAL
anti-CD19 chimeric antigen receptor - transduced T-cell given IV
FludarabineDRUG
given IV
CyclophosphamideDRUG
given IV
TocilizumabDRUG
given IV
CytarabineDRUG
given IV
EtoposideDRUG
given IV
DexamethasoneDRUG
given IV

Study Locations

FacilityCityStateCountry
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and ImmunologyMoscowRussia

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026